St John’s wort as treatment for depression

I read with interest the paper¹ by van Gurp et al on use of St John’s wort (SJW) for depression. This paper exhibits some elements that merit comment.

A general problem with psychotherapeutic trials is that the very act of being in a study and receiving attention has salutary effects. The challenge is to demonstrate that the putative therapy is superior to placebo. It has been recognized for some time that mild forms of depression tend to improve just as much with placebo as with antidepressants.² This phenomenon certainly is consistent with many of the European trials of antidepressants, which found no difference between placebo and active therapy.³ ⁴

The reduction in scores on the Hamilton Rating Scale for Depression (Ham-D) noted in this paper for both SJW patients, they would likely have improved more.

The authors’ conclusion that SJW has a role as a first treatment option for mild-to-moderate depression is not supported by this study. The best that can be said is that two agents that would be expected to act as placebos did precisely that. In these circumstances, favouring one agent because of a lower side effect profile would seem to lend more support to simply giving a sugar pill rather than a herbal compound with its attendant risks.

—Lloyd Oppel, MD, CCFP(RM)
Vancouver, BC
by e-mail

References

Response

We thank Dr Oppel for his interest and his observations. Our aim was to conduct a trial on primary care patients treated by family physicians. We deliberately selected a lower Ham-D inclusion criterion in order to accurately reflect the less severe forms of major depression in this population. As Dr Oppel notes, recent evidence suggests that milder forms of major depression might improve as much with placebo as with antidepressants. At the time of study design, standard therapy for even less severe forms of major depression included prescription of an antidepressant agent. The idea was to compare standard treatment with an alternative herbal treatment: St John’s wort (SJW).

Dr Oppel’s comments are based mainly on a review of a Food and Drug Administration database of 45 antidepressant clinical trials.¹ The authors of the review concluded that, in studies where mean pretreatment Ham-D scores were 24 or less, antidepressants performed no better than placebo.

To explore this issue, we examined treatment response in patients with pretreatment Ham-D scores 24 or higher (n = 11) and in patients with scores lower than 24 (n = 76). There was no interaction between pretreatment Ham-D scores and study outcomes. In both study groups, the mean decline in Ham-D score from baseline to 12 weeks was similar among those with higher and lower baseline Ham-D scores.

Dr Oppel also refers to a difference in compliance between the two treatment groups. In fact, compliance was similar. What was different was that the sertraline patients reported adverse effects roughly twice as frequently as the SJW patients.

We doubt that, on the strength of evidence currently available, family physicians would be comfortable with withholding antidepressant therapy from all but the most severely depressed patients. Until future research supports such a departure from current practice, our data suggest that SJW is a reasonable first treatment option in this population given its apparently similar effectiveness and more favourable side effect profile when compared with selective serotonin reuptake inhibitors. Physicians should be aware of potential interactions with anticonvulsants, warfarin, oral contraceptives, digoxin, and anti-retroviral agents.

—Gerald van Gurp, MD
—Greg Meterissian, MD, FRCP(C)
—Laura Haiek, MD, MSC
—Jane McCusker, MD, DRPH
—François Bellavance, PhD

Reference